Contact
searchSearch
HMP Global
Login

News

News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with...
07/02/2026
Oncology
News
Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3 ASTRUM-005 trial demonstrated that serplulimab plus carboplatin and etoposide continued to improve long-term overall survival compared with chemotherapy alone in patients with previously untreated...
Updated results from the phase 3...
07/02/2026
Oncology
News
Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study demonstrated that first-line chemoimmunotherapy significantly improved overall survival and progression-free survival compared with chemotherapy alone in patients with extensive-stage small cell lung cancer,...
Results from a real-world study...
07/02/2026
Oncology
News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
Ivonescimab Plus Liposomal Irinotecan Demonstrates Second-Line Promise in Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
177Lu-Satoreotide Tetraxetan Shows Strong Preliminary Efficacy and Safety in Extensive-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1 LuSato-1 study suggest that combining maintenance immunotherapy with 177Lu-satoreotide tetraxetan demonstrates promising preliminary clinical efficacy and safety in patients with in extensive-stage small cell lung...
Results from the phase 1...
06/09/2026
Oncology
News
Autologous NK Cell Consolidation Improves Survival Outcomes in Limited-Stage Small Cell Lung Cancer
06/09/2026
Emily Estrada
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.
Results from a phase 2 study...
06/09/2026
Oncology

Recent News

News
Alpha DaRT® Plus Pembrolizumab Achieves 100% Response Rate in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/21/2026
Stephanie Holland
Results from a prospective study demonstrated that Alpha DaRT® combined with pembrolizumab achieved a 100% systemic objective response rate among evaluable patients with recurrent unresectable or metastatic head and neck squamous cell...
Results from a prospective study demonstrated that Alpha DaRT® combined with pembrolizumab achieved a 100% systemic objective response rate among evaluable patients with recurrent unresectable or metastatic head and neck squamous cell...
Results from a prospective study...
07/21/2026
Oncology
News
Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma
07/21/2026
Emily Estrada
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase...
07/21/2026
Oncology
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
News
Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer
07/16/2026
Stephanie Holland
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the...
07/16/2026
Oncology
FDA Approval
FDA Approves Gedatolisib-Based Regimens for PIK3CA Wild-Type HR-Positive, HER2-Negative Advanced Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in...
07/14/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
07/14/2026
Stephanie Holland
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional...
07/14/2026
Oncology
News
De-escalated Paclitaxel, Trastuzumab, and Pertuzumab Yield Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the...
07/14/2026
Oncology
FDA Approval
FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome
07/13/2026
Stephanie Holland
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a...
07/13/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use